{2 (5.5 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) / 11 (8.3 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) } Pack
- RxCUI
- 2630779
- RxNorm name
- {2 (5.5 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) / 11 (8.3 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) } Pack
- Display name
- {2 (5.5 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) / 11 (8.3 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) } Pack
- Full name
- {2 (5.5 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) / 11 (8.3 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) } Pack
- Term type
- GPCK
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:02
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125694 | Zolgensma | onasemnogene abeparvovec-xioi | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Zolgensma | ONASEMNOGENE ABEPARVOVEC-XIOI | Novartis Innovative Technologies Inc. | 68cd4f06-70e1-40d8-bedb-609ec0afa471 | 2026-06-16 | Boxed warning, Warnings, Adverse reactions | 2630779 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 68cd4f06-70e1-40d8-bedb-609ec0afa471 | {2 (5.5 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) / 11 (8.3 ML onasemnogene abeparvovec-xioi 20000000000000 VECTOR-GENOMES/ML Injection) } Pack | GPCK | 14 | These highlights do not include all the information needed to use ZOLGENSMA safely and effectively. See full prescribing information for ZOLGENSMA. ZOLGENSMA ® (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion Initial U.S. Approval: 2019 | 20251218 |
| 68cd4f06-70e1-40d8-bedb-609ec0afa471 | onasemnogene abeparvovec-xioi Kit Patient Weight 18.1 - 18.5 KG | PSN | 14 | These highlights do not include all the information needed to use ZOLGENSMA safely and effectively. See full prescribing information for ZOLGENSMA. ZOLGENSMA ® (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion Initial U.S. Approval: 2019 | 20251218 |
| 68cd4f06-70e1-40d8-bedb-609ec0afa471 | onasemnogene abeparvovec-xioi Kit Patient Weight 18.1 - 18.5 KG | SY | 14 | These highlights do not include all the information needed to use ZOLGENSMA safely and effectively. See full prescribing information for ZOLGENSMA. ZOLGENSMA ® (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion Initial U.S. Approval: 2019 | 20251218 |